Myocardial infarction in a patient with multiple sclerosis after receiving natalizumab

Natalizumab is among the most effective drugs for controlling multiple sclerosis (MS). The most important side effect of this drug is progressive multifocal leukoencephalopathy, although some other complications are increasingly reported in literature such as meningitis and encephalitis. Here, a patient with MS who has suffered from myocardial infarction (MI) after the injection of natalizumab is introduced.